Director/PDMR Shareholding

RNS Number : 4524H

Yourgene Health PLC

01 August 2019

 

Yourgene Health plc

("Yourgene" or the "Company")

Director / PDMR Shareholding

Manchester, UK - 1 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday that Hayden Jeffreys, Chief Operating Officer and a director of the Company, purchased 83,512 ordinary shares of 0.10p each in the Company yesterday at a price of 11.96 pence per ordinary share.

Following the purchase, Hayden Jeffreys holds 305,860 ordinary shares in the Company representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing [e-mail]	Tel: [phone]
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie / Ludovico Lazzaretti	Tel: [phone]
Stifel Nicolaus Europe Limited (Broker) Nicholas Moore / Matthew Blawat / Ben Maddison	Tel: [phone]
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne / Anna Dunphy	Tel: [phone] or [e-mail] Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Hayden Jeffreys
2	Reason for notification
a.	Position/Status	Chief Operating Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Yourgene Health plc
b.	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.10p each ISIN: GB00BN31ZD89
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			11.96p	83,512
e.	Date of the transaction	31 July 2019
f.	Place of the transaction	London Stock Exchange

 

END

 

 

DSHQFLFXKDFXBBD